JP4503849B2 - Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段 - Google Patents

Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段 Download PDF

Info

Publication number
JP4503849B2
JP4503849B2 JP2000581189A JP2000581189A JP4503849B2 JP 4503849 B2 JP4503849 B2 JP 4503849B2 JP 2000581189 A JP2000581189 A JP 2000581189A JP 2000581189 A JP2000581189 A JP 2000581189A JP 4503849 B2 JP4503849 B2 JP 4503849B2
Authority
JP
Japan
Prior art keywords
pge
polypeptide
pge synthase
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000581189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539762A (ja
JP2002539762A5 (enExample
Inventor
ヤコブソン，ペル−ヨハン
サミュエルソン，ベングト
モルゲンシュテルン，ラルフ
マンチーニ，ジョゼフ
フォード−ハッチンソン，アンソニー
Original Assignee
カロリンスカ インスティチュテート イノベーションズ アクティエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カロリンスカ インスティチュテート イノベーションズ アクティエボラーグ filed Critical カロリンスカ インスティチュテート イノベーションズ アクティエボラーグ
Publication of JP2002539762A publication Critical patent/JP2002539762A/ja
Publication of JP2002539762A5 publication Critical patent/JP2002539762A5/ja
Application granted granted Critical
Publication of JP4503849B2 publication Critical patent/JP4503849B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
JP2000581189A 1998-11-09 1999-11-02 Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段 Expired - Lifetime JP4503849B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10768798P 1998-11-09 1998-11-09
US60/107,687 1998-11-09
PCT/EP1999/008363 WO2000028022A1 (en) 1998-11-09 1999-11-02 Pge synthase and methods and means for modulating its activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010011053A Division JP2010115205A (ja) 1998-11-09 2010-01-21 Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段

Publications (3)

Publication Number Publication Date
JP2002539762A JP2002539762A (ja) 2002-11-26
JP2002539762A5 JP2002539762A5 (enExample) 2006-12-14
JP4503849B2 true JP4503849B2 (ja) 2010-07-14

Family

ID=22317930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000581189A Expired - Lifetime JP4503849B2 (ja) 1998-11-09 1999-11-02 Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段
JP2010011053A Pending JP2010115205A (ja) 1998-11-09 2010-01-21 Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010011053A Pending JP2010115205A (ja) 1998-11-09 2010-01-21 Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段

Country Status (9)

Country Link
US (4) US6395502B1 (enExample)
EP (1) EP1129188B1 (enExample)
JP (2) JP4503849B2 (enExample)
AT (1) ATE305040T1 (enExample)
AU (1) AU770307B2 (enExample)
CA (1) CA2349529C (enExample)
DE (1) DE69927400T2 (enExample)
ES (1) ES2249042T3 (enExample)
WO (1) WO2000028022A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität
WO2001057225A1 (fr) * 2000-02-03 2001-08-09 Chugai Seiyaku Kabushiki Kaisha Proteine regissant l'activite de la pge2 synthase et son utilisation
AU2002323358A1 (en) * 2001-08-24 2003-03-10 Karoliska Innovations Ab Methods for preparing purified prostaglandin e synthase
IL161831A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Disruption of the prostaglandin e synthase 2 gene
EP1575498A2 (en) * 2002-09-25 2005-09-21 Pharmacia Corporation Antisense modulation of microsomal prostaglandin e2 synthase expression
WO2004067766A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide h2
WO2005024059A2 (en) * 2003-09-09 2005-03-17 Karolinska Innovations Ab Methods for identifying compounds for inhibiting fever
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
CA2639412A1 (en) * 2007-09-11 2009-03-11 Universite Laval Prostaglandin e2 modulation and uses thereof
CN117323320B (zh) * 2023-11-20 2025-10-31 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US914356A (en) * 1901-11-30 1909-03-02 Harry Ward Leonard Electric-circuit controller.
EP1015624A2 (en) * 1997-09-17 2000-07-05 The Johns Hopkins University P53-induced apoptosis
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität

Also Published As

Publication number Publication date
CA2349529C (en) 2009-10-27
US7192733B2 (en) 2007-03-20
DE69927400D1 (de) 2006-02-02
US7067296B2 (en) 2006-06-27
US20030064493A1 (en) 2003-04-03
ATE305040T1 (de) 2005-10-15
AU1504100A (en) 2000-05-29
JP2002539762A (ja) 2002-11-26
US6395502B1 (en) 2002-05-28
WO2000028022A1 (en) 2000-05-18
AU770307B2 (en) 2004-02-19
US7645601B2 (en) 2010-01-12
CA2349529A1 (en) 2000-05-18
EP1129188A1 (en) 2001-09-05
JP2010115205A (ja) 2010-05-27
ES2249042T3 (es) 2006-03-16
EP1129188B1 (en) 2005-09-21
DE69927400T2 (de) 2006-06-29
US20050118696A1 (en) 2005-06-02
US20080153107A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
JP2010115205A (ja) Ｐｇｅシンターゼおよびその活性をモジュレートする方法及び手段
Manilal et al. The Emery-Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein
De Vries et al. RGS-GAIP, a GTPase-activating Protein for GαiHeterotrimeric G Proteins, Is Located on Clathrin-coated Vesicles
Ruan et al. Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum.
JP2002017353A (ja) 変性ｌｄｌの定量方法
IL205793A (en) Polymeric-2 Polymeric Polypeptide of Vertebrates Spotted to Heterologous Amino Acid Sequence
JP4033490B2 (ja) ホスファターゼモデュレーター
US7033771B2 (en) Use of insulin response modulators in the treatment of diabetes and insulin resistance
AU2003271297B2 (en) PGE synthase and methods and means for modulating its activity
US20030220238A1 (en) BFIT compositions and methods of use
WO2005019472A1 (ja) シノビオリン活性調節作用の検出方法
JPH10117788A (ja) ヒト・ｍｙｔ−１キナーゼクローン
Fik-Rymarkiewicz et al. Novel frequenin-modulated Ca2+-signaling membrane guanylate cyclase (ROS-GC) transduction pathway in bovine hippocampus
Svartz et al. Leukotriene C4 synthase homo-oligomers detected in living cells by bioluminescence resonance energy transfer
US20090312245A1 (en) SRA binding protein
AU780821B2 (en) Coupling factor 6 inhibitor and potentiator and use thereof
US6262234B1 (en) Nuclear receptor polypeptide ZPPAR4
US20030087387A1 (en) Human toll homologues
US20020164650A1 (en) Methods of assessing wolframin protein activity
US20040161803A1 (en) Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
WO2002079501A1 (en) Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
JP2002300880A (ja) 新規ユビキチン特異プロテアーゼ
WO2002090932A2 (en) Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
JPH10201488A (ja) ヒトミオトロフィンクローン、ｈｓａｂｈ０１
WO2002093128A2 (en) Identifying insulin response modulators and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100323

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100422

R150 Certificate of patent or registration of utility model

Ref document number: 4503849

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130430

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140430

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term